Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Venetoclax in High-Risk Stage A CLL (FILO)
2018-001475-20Phase 2Active
- Sponsor
- Filo
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Filo. Primary endpoint: Complete response rate with MRD negativity in bone marrow at 12 months. Started Oct 2018; status: active.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-001475-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001475-20.